Compare GSK plc (GSK) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kroger Co — how do they compare? GSK plc trades at $52.76 (market cap $101.34B), while Kroger Co trades at $57.66 (market cap $34.65B). The key difference: GSK plc is far larger — about 2.9× Kroger Co's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | KR | |
|---|---|---|
Market Cap | $101.34B | $34.65B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $75.60 |
52-Week Low | $36.20 | $55.53 |
Enterprise Value | $121.95B | $54.75B |
Dividend Yield | 3.49% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Kroger (KR) trades at $58.74, down 0.96% today, with a bearish technical outlook despite recent earnings beats. The company maintains stable revenue around $147B with improving net margins to 1.81% in 2025. Recent acquisition of Giant Eagle for $1.65 billion expands Midwest presence, while Berkshire Hathaway ownership provides institutional confidence. Valuation shows mixed signals with low P/S of 0.28 but elevated P/E of 55.29.
KR offers defensive exposure with dividend yield support, but faces competitive grocery wars and margin pressure. Analyst consensus targets $68.63 (17% upside) with 48% buy ratings. Key risks include integration execution of Giant Eagle deal and industry pricing pressures. Cash flow strength supports dividend sustainability despite negative ROE.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
